Form 4: BioSig Technologies Director Acquires Shares in Lieu of Cash Compensation

Frederick Hrkac, a director at BioSig Technologies, acquired 23,345 shares of common stock in lieu of cash compensation for board fees.

Summary

• On April 24, 2025, Frederick Hrkac, a director of BioSig Technologies, Inc., acquired 23,345 shares of common stock.
• The acquisition was made in lieu of cash compensation for Q4 2024 and Q1 2025 board fees.
• The shares were granted under the company's 2023 Equity Incentive Plan and were fully vested on the date of grant.
• The closing price of BioSig Technologies' common stock on April 24, 2025, was $0.84 per share.
• Following the transaction, Hrkac beneficially owns 612,846 shares of BioSig Technologies.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard compensation practice. The director's acceptance of shares could be seen as a positive signal, but it's primarily a procedural matter.

Positives

• The acquisition of shares by a director demonstrates confidence in the company.
• Using equity in lieu of cash preserves the company's cash reserves.

Industry Context

Directors receiving stock in lieu of cash compensation is a common practice, especially for smaller companies, to conserve cash.

Stakeholder Impact

• Shareholders may view the director's stock acquisition positively.
• The company benefits from preserving cash by issuing stock instead of cash compensation.

Key Dates

Keywords

BioSig Technologies, BSGM, Form 4, Director, Share Acquisition, Equity Incentive Plan, Frederick Hrkac, Compensation